The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Monoamine Oxidase Inhibitors
Adams & Victors Principles of Neurology Chp 43, pg 1210, Ropper, A.H.,et al, 2014
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Safety of Rasagiline in Elderly Patients with Parkinson Disease
Neurol 66:1427-1429, Goetz,C.G.,et al, 2006
Serotonin Syndrome Induced by Transitioning from Phenelzine to Venlafaxine:four Patient Reports
Neurol 51:274-276, Diamond,S.,et al, 1998
Selegiline and Mortality in Parkinson's Disease
Ann Neurol 40:841-845, Olanow,C.W.,et al, 1996
The Use of Sumatriptan in Patients with Monoamine Oxidase Inhibitors
Neurol 45:1039-1040, Diamond,S., 1995
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993
Deprenyl Effects of Levodopa Pharmacodynamics, Mood, and Free Radical Scavenging
Neurol 42:541-544, Baronti,F.,et al, 1992
Severe Adverse Interaction Between Pethidine and Selegiline
Lancet 337:246, Zornberg,G.L.,et al, 1991
Pergolide and Selegiline for Parkinson's Disease
The Medical Letter, 31:81-841989., , 1989
Phenelzine Toxicity Responsive to Dantrolene
Neurol 37:865-867, Verrilli,M.R.,et al, 1987
MPTP:A Neurotoxin Relevant to the Pathophysiology of Parkinson's Disease, The 1985 George Cotzias Lecture
Neurol 36:250-258, Snyder,S.H.&D'Amato,R.J., 1986
Pyridoxine Deficiency & Peripheral Neuropathy Associated with Long-Term Phenelzine Therapy
Am J Med 75:887-888, Heller,C.A.,et al, 1983
Considerations in the Management of Parkinsonism
Neurol 28:5, Fahn,S.,et al, 1978
Postural Hypotension:Adrenergic Responsivity, & Levodopa Therapy
Neurol 27:921, Corder,C.N.,et al, 1977
Drug Therapy of Parkinsonism
NEJM 295:814, Bianchine,J.R., 1976
Neuropharmacological Aspects of Migraine
Editorial, BMJ 339, 1975, Aug., , 1975
Neurotoxicity of Commonly Used Antineoplastic Agents
NEJM 291:75, 1271974., Weiss,H.,et al, 1974
Drug Therapy of Parkinsonism
NEJM 287:20, Yahr,M.,et al, 1972
Monoamine Oxidase Inhibitor & L-Dopa
BMJ 3:388, Hunter,H.R.,et al, 1970
Neuropsychopharmcology & the Affective Disorders
NEJM 281:197, 1969 (three parts) ., Schildkraut,J.J., 1969